Your session is about to expire
← Back to Search
JSP191 + Stem Cell Transplant for Sickle Cell Anemia
Study Summary
This trial is testing if a new antibody drug (JSP191) improves the success of a blood stem cell transplant for people with sickle cell disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I meet one disease category and all required conditions.I am at least 4 years old, weigh 20 kg or more, and willing to donate stem cells and blood for research.I have beta-thalassemia with moderate to severe iron overload.I am between 11 and 15 years old.I am between 6 and 10 years old.I am at least 4 years old (or 18 for the first part of the study).My donor is a complete HLA match.I have sickle cell disease with complications not improved by current treatments.I am mostly bedridden due to my health condition.I do not have any major illnesses that would make a stem cell transplant impossible.I have a family donor who is a complete match for me.
- Group 1: briquilimab in stem cell transplant recipients for SCD
- Group 2: Stem cell Donors of Recipients undergoing stem cell transplant
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment for this clinical trial still open?
"This clinical study, first listed on May 12th 2022, is still actively searching for participants. As of October 4th 2022 it has been updated to reflect the latest information."
To what extent is patient participation in this trial expanding?
"Affirmative. According to information found on clinicaltrials.gov, this trial is actively seeking participants and began recruitment on May 12th 2022 with the most recent edit occurring October 4th 2022. 90 individuals are needed at a single site for enrolment into the study."
Who else is applying?
What state do they live in?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger